+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antiparasitic Drugs Market - Global Forecast 2026-2032- Product Image
Antiparasitic Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Antiparasitic Drugs Market - Global Forecast 2026-2032

  • Report

  • 187 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 5715672
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antiparasitic Drugs Market is projected to reach USD 23.30 Billion in 2026. It is expected to continue growing at a CAGR of 4.88%, reaching USD 30.98 Billion by 2032.

Antiparasitic drugs remain a critical pillar of global infectious disease control, spanning antimalarials, anthelmintics, antiprotozoals, ectoparasiticides, and therapies for neglected tropical diseases. Demand is shaped by persistent parasitic disease burdens, expanding travel and migration, climate-sensitive vector ecology, antimicrobial and antiparasitic resistance, veterinary-to-human health linkages, and public health campaigns focused on prevention, diagnosis, and treatment access. The category is strategically important because parasitic infections affect both high-burden endemic settings and advanced healthcare systems managing imported infections, immunocompromised patients, and resistance surveillance. Key priorities across the antiparasitic drugs landscape include improving treatment efficacy, reducing toxicity, simplifying dosing, expanding pediatric and pregnancy-appropriate options, strengthening pharmacovigilance, and ensuring resilient supply chains for essential medicines. Policy frameworks from global health agencies, national malaria programs, deworming initiatives, and neglected tropical disease roadmaps continue to guide procurement, access, and rational use. As stakeholders address evolving parasite biology and health system constraints, the competitive focus is shifting toward differentiated formulations, combination regimens, diagnostics-linked prescribing, and equitable access models that support measurable public health outcomes.

Transformative Shifts in the Antiparasitic Drugs Landscape

The antiparasitic drugs landscape is being reshaped by resistance management, integrated disease control, and greater alignment between human, animal, and environmental health. Artemisinin partial resistance in malaria-endemic regions, resistance concerns in helminth control programs, and reduced susceptibility patterns in several protozoal infections are increasing the need for robust surveillance, combination therapy strategies, and stewardship-focused prescribing. At the same time, mass drug administration programs for soil-transmitted helminths, schistosomiasis, lymphatic filariasis, and onchocerciasis continue to influence medicine selection, procurement requirements, and pharmacovigilance standards. Diagnostic transformation is also changing treatment pathways, as rapid tests, molecular assays, and point-of-care tools improve case confirmation and reduce inappropriate use. Climate variability, urbanization, deforestation, and changing mosquito and tick habitats are expanding the geographic relevance of vector-borne parasitic infections, including malaria, leishmaniasis, Chagas disease, babesiosis, and other emerging threats. Regulatory expectations are becoming more evidence-intensive, with emphasis on quality-assured manufacturing, bioequivalence, pediatric dosing, safety in vulnerable populations, and post-marketing monitoring. These shifts are creating opportunities for therapies that are easier to administer, compatible with public health distribution, effective against resistant strains, and supported by reliable diagnostic and surveillance ecosystems.

Cumulative Impact of Artificial Intelligence on Antiparasitic Drugs

Artificial intelligence is increasingly influencing antiparasitic drug discovery, development, surveillance, and access planning. AI-enabled molecular screening can accelerate identification of novel antiparasitic targets, optimize lead compounds, and support repurposing of existing medicines against diseases such as malaria, leishmaniasis, Chagas disease, schistosomiasis, and other neglected tropical diseases. Machine learning models are being applied to parasite genomics, resistance markers, and pharmacological datasets to improve understanding of treatment failure patterns and inform next-generation combination strategies. In clinical and public health settings, AI-supported image analysis is improving parasite detection in microscopy workflows, while predictive analytics can help map transmission risk by integrating climate, mobility, vector, and health system data. These capabilities are especially relevant for early warning systems in malaria elimination settings and for targeting interventions in regions affected by neglected tropical diseases. AI also supports pharmacovigilance by detecting safety signals from real-world data and improving supply planning for essential antiparasitic medicines. However, the impact of artificial intelligence depends on high-quality datasets, representative disease burden information, transparent model validation, privacy safeguards, and equitable deployment in low-resource settings. Industry leaders that combine AI with field epidemiology, regulatory-grade evidence, and local implementation partnerships are better positioned to improve antiparasitic innovation and treatment access.

Key Regional Insights Across Antiparasitic Drug Demand

Asia-Pacific remains central to the antiparasitic drugs landscape due to large populations exposed to malaria, soil-transmitted helminths, lymphatic filariasis, dengue-associated diagnostic complexity, and foodborne parasitic infections, with Southeast Asia also playing a key role in resistance surveillance for malaria therapies. North America is shaped by imported parasitic infections, travel medicine, immunocompromised patient management, tick-borne parasitic disease monitoring, veterinary parasite control, and public health attention to diseases such as Chagas disease in at-risk populations. Latin America carries significant relevance for Chagas disease, leishmaniasis, malaria transmission in selected areas, and strong public health engagement in vector control and screening, particularly where migration and rural exposure influence diagnosis and care. Europe is characterized by stringent regulatory oversight, imported infection management, migrant health programs, and surveillance of emerging vector-borne risks as climate conditions affect vector distribution. The Middle East presents a mixed profile, with leishmaniasis, imported malaria, travel-related parasitic infections, and mass gathering health preparedness influencing demand for diagnostics and therapies. Africa remains the highest-priority region for many antiparasitic interventions because of the substantial burden of malaria, schistosomiasis, lymphatic filariasis, onchocerciasis, soil-transmitted helminths, and other neglected tropical diseases, making access to quality-assured medicines, community-based delivery, and resistance monitoring essential to disease control outcomes.

Key Group Insights Shaping Antiparasitic Drug Priorities

ASEAN countries are strategically important for antiparasitic drugs because they combine high population mobility, tropical transmission conditions, malaria elimination goals, helminth control programs, and historical evidence of antimalarial resistance emergence in parts of the Greater Mekong Subregion. The GCC is influenced by imported infections, expatriate workforce health, travel medicine, pilgrimage-related preparedness, and public health screening programs, creating a focus on diagnosis, access, and rapid treatment pathways. The European Union emphasizes regulatory harmonization, pharmacovigilance, antimicrobial stewardship principles, cross-border surveillance, migrant health, and research support for neglected tropical diseases, making evidence quality and safety monitoring central to adoption. BRICS countries collectively represent diverse antiparasitic priorities, including malaria and helminth control in endemic areas, Chagas disease and leishmaniasis programs, large-scale manufacturing capabilities, and expanding investment in domestic pharmaceutical capacity. G7 countries are major contributors to global health financing, research infrastructure, regulatory science, and imported disease management, supporting innovation in diagnostics, medicines, and surveillance. NATO members, while not a healthcare market grouping, maintain relevance through military medicine, deployment health, travel-related infection prevention, and readiness planning for personnel operating in parasite-endemic environments, where prophylaxis, treatment protocols, and supply reliability are operational priorities.

Key Country Insights for Antiparasitic Drug Strategy

The United States focuses on travel-related parasitic infections, Chagas disease awareness, tick-borne disease surveillance, and access to therapies for rare or imported conditions, while Canada shares similar priorities with additional emphasis on migrant health, northern and indigenous health considerations, and travel medicine. Mexico and Brazil are highly relevant in Latin America because of Chagas disease, leishmaniasis, malaria in selected regions, and vector control programs, with Brazil also maintaining extensive public health infrastructure for neglected tropical disease surveillance. The United Kingdom, Germany, France, Italy, and Spain are shaped by imported parasitic infections, migrant health, tropical medicine expertise, and strict regulatory and reimbursement expectations, while southern European countries face increasing attention to vector-borne risks linked to changing climate and travel patterns. Russia presents a distinct profile involving regional parasitic disease surveillance, imported infections, and veterinary-linked parasitic risks. China and India are pivotal due to large populations, domestic pharmaceutical manufacturing capacity, malaria elimination progress, helminth control efforts, and significant research and public health activity; India also remains central to mass drug administration and neglected tropical disease programs. Japan and South Korea emphasize high regulatory standards, travel medicine, imported infection preparedness, and advanced diagnostics, while Australia combines travel-related care with regional engagement in Asia-Pacific disease control and surveillance of parasitic risks relevant to tropical and remote communities.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize resistance-aware innovation by investing in novel mechanisms of action, validated combination regimens, and surveillance-linked development strategies. Portfolio planning should address unmet needs in pediatric, pregnancy-compatible, immunocompromised, and low-resource populations while improving tolerability, dosing simplicity, heat stability, and adherence. Strengthening diagnostic partnerships is essential because test-and-treat models can improve appropriate prescribing and reduce unnecessary drug exposure. Manufacturers and distributors should improve supply resilience for essential antiparasitic medicines by diversifying sourcing, maintaining quality-assured production, and aligning with public health procurement standards. Regulatory strategy should incorporate global evidence expectations, local endemicity data, pharmacovigilance systems, and real-world safety monitoring. Partnerships with public health agencies, academic networks, and community health programs can improve access and implementation in endemic regions. Leaders should also use AI and data analytics responsibly to support drug discovery, risk mapping, demand planning, and safety surveillance, while ensuring models are transparent, validated, and representative of populations most affected by parasitic diseases.

Research Methodology

This executive summary is developed through a structured secondary research methodology focused on verified, data-backed public health and pharmaceutical intelligence. The analysis draws on authoritative sources such as international health agencies, national disease control programs, peer-reviewed journals, regulatory guidance, essential medicines frameworks, pharmacovigilance references, and recognized infectious disease surveillance publications. Evidence is assessed across disease burden, treatment guidelines, resistance patterns, regulatory priorities, public health procurement, diagnostic adoption, and regional epidemiology. Qualitative synthesis is used to identify strategic themes without presenting market sizing, market share, market estimation, or forecasting. Regional, group, and country insights are organized around epidemiological relevance, healthcare system priorities, access dynamics, and policy alignment. The methodology emphasizes source triangulation, recency, clinical relevance, and consistency across public health datasets and regulatory documentation. Where disease dynamics vary by locality, insights are presented in a directional and contextual manner to avoid unsupported generalization.

Conclusion

The antiparasitic drugs landscape is entering a more complex and strategically significant phase as resistance, climate-sensitive transmission, migration, diagnostic modernization, and public health access goals reshape treatment priorities. Sustainable progress depends on medicines that are effective, safe, affordable, quality-assured, and supported by surveillance systems capable of detecting resistance and guiding rational use. Regional needs differ substantially, from malaria and neglected tropical disease control in high-burden settings to imported infection management and emerging vector surveillance in advanced healthcare systems. Artificial intelligence, improved diagnostics, and integrated One Health approaches can accelerate innovation, but their value depends on strong data quality, regulatory-grade validation, and equitable deployment. Organizations that align product development, access strategy, quality systems, and public health partnerships will be best positioned to address the evolving global burden of parasitic diseases while supporting measurable improvements in treatment outcomes and disease control.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Antiparasitic Drugs Market, by Drug Class
7.1. Introduction
7.2. Benzimidazoles
7.2.1. Albendazole
7.2.2. Fenbendazole
7.2.3. Mebendazole
7.2.4. Oxibendazole
7.2.5. Thiabendazole
7.3. Macrocyclic Lactones
7.3.1. Abamectin
7.3.2. Doramectin
7.3.3. Eprinomectin
7.3.4. Ivermectin
8. Antiparasitic Drugs Market, by Veterinary
8.1. Introduction
8.2. Aquaculture
8.2.1. Fish
8.2.2. Shrimp
8.3. Companion Animals
8.3.1. Canine
8.3.2. Feline
8.4. Livestock
8.4.1. Cattle
8.4.2. Poultry
8.4.3. Swine
9. Antiparasitic Drugs Market, by Dosage Form
9.1. Introduction
9.2. Tablets
9.3. Capsules
9.4. Suspensions
9.5. Syrups
9.6. Injectable Solutions
9.7. Creams & Ointments
9.8. Lotions
9.9. Powders
10. Antiparasitic Drugs Market, by Spectrum of Activity
10.1. Introduction
10.2. Broad-spectrum antiparasitics
10.3. Narrow-spectrum antiparasitics
11. Antiparasitic Drugs Market, by Route of Administration
11.1. Introduction
11.2. Oral
11.3. Injectable
12. Antiparasitic Drugs Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Antiparasitic Drugs Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Antiparasitic Drugs Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Adva Care Pharma
16.2. Algen Healthcare Ltd.
16.3. Amneal Pharmaceuticals LLC
16.4. Bayer AG
16.5. Ben Pharmaceuticals
16.6. Centurion Laboratories Private Limited
16.7. Cipla Ltd.
16.8. Consern Pharma Limited
16.9. Dr.Reddys Laboratories Inc.
16.10. F. Hoffmann-La Roche AG
16.11. Fredun Group
16.12. Garcia Life Sciences
16.13. Glaxosmithkline PLC
16.14. Healthy Life Pharma Private Limited
16.15. Ipca Laboratories
16.16. Jackson Laboratories Pvt Ltd.
16.17. Mankind Pharma
16.18. Merck KgaA
16.19. Novartis AG
16.20. Sanofi
16.21. Soigner Pharma by Arlak Biotech
16.22. Sriwalls Health Care
16.23. Taj Life Sciences Pvt. Ltd.
16.24. Weefsel Pharma
16.25. Zydus Group
17. Key Experts
List of Figures
FIGURE 1. Global Antiparasitic Drugs Market, Years Considered for the Study
FIGURE 2. Global Antiparasitic Drugs Market, Research Design
FIGURE 3. Global Antiparasitic Drugs Market, Research Framework
FIGURE 4. Global Antiparasitic Drugs Market, Data Triangulation
FIGURE 5. Global Antiparasitic Drugs Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Antiparasitic Drugs Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 7. Global Antiparasitic Drugs Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Antiparasitic Drugs Market Size, by Veterinary, 2025 vs 2032 (%)
FIGURE 9. Global Antiparasitic Drugs Market Size, by Veterinary, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Antiparasitic Drugs Market Size, by Dosage Form, 2025 vs 2032 (%)
FIGURE 11. Global Antiparasitic Drugs Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Antiparasitic Drugs Market Size, by Spectrum of Activity, 2025 vs 2032 (%)
FIGURE 13. Global Antiparasitic Drugs Market Size, by Spectrum of Activity, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Antiparasitic Drugs Market Size, by Route of Administration, 2025 vs 2032 (%)
FIGURE 15. Global Antiparasitic Drugs Market Size, by Route of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Antiparasitic Drugs Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Antiparasitic Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Antiparasitic Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Antiparasitic Drugs Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Antiparasitic Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Antiparasitic Drugs Market Share, by Key Player, 2025
List of Tables
TABLE 1. Global Antiparasitic Drugs Market Segmentation & Coverage
TABLE 2. Global Antiparasitic Drugs Market Size, 2017-2032 (USD Million)
TABLE 3. Global Antiparasitic Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 4. Global Benzimidazoles Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Benzimidazoles Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Benzimidazoles Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Albendazole Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Albendazole Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Albendazole Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Fenbendazole Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Fenbendazole Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Fenbendazole Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Mebendazole Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Mebendazole Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Mebendazole Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Oxibendazole Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Oxibendazole Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Oxibendazole Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Thiabendazole Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Thiabendazole Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Thiabendazole Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Macrocyclic Lactones Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Macrocyclic Lactones Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Macrocyclic Lactones Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Abamectin Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Abamectin Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Abamectin Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Doramectin Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Doramectin Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Doramectin Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Eprinomectin Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Eprinomectin Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Eprinomectin Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Ivermectin Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Ivermectin Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Ivermectin Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Antiparasitic Drugs Market Size, by Veterinary, 2017-2032 (USD Million)
TABLE 38. Global Aquaculture Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Aquaculture Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Aquaculture Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Fish Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Fish Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Fish Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Shrimp Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Shrimp Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Shrimp Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Companion Animals Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Companion Animals Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Companion Animals Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Canine Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Canine Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Canine Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Feline Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Feline Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Feline Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Livestock Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Livestock Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Livestock Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Cattle Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Cattle Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Cattle Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Poultry Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Poultry Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Poultry Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Swine Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Swine Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Swine Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Antiparasitic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 69. Global Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Tablets Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Capsules Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Global Capsules Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. Global Capsules Market Size, by Country, 2017-2032 (USD Million)
TABLE 75. Global Suspensions Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global Suspensions Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global Suspensions Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Syrups Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Syrups Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Syrups Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Injectable Solutions Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Global Injectable Solutions Market Size, by Group, 2017-2032 (USD Million)
TABLE 83. Global Injectable Solutions Market Size, by Country, 2017-2032 (USD Million)
TABLE 84. Global Creams & Ointments Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Global Creams & Ointments Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. Global Creams & Ointments Market Size, by Country, 2017-2032 (USD Million)
TABLE 87. Global Lotions Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Global Lotions Market Size, by Group, 2017-2032 (USD Million)
TABLE 89. Global Lotions Market Size, by Country, 2017-2032 (USD Million)
TABLE 90. Global Powders Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Global Powders Market Size, by Group, 2017-2032 (USD Million)
TABLE 92. Global Powders Market Size, by Country, 2017-2032 (USD Million)
TABLE 93. Global Antiparasitic Drugs Market Size, by Spectrum of Activity, 2017-2032 (USD Million)
TABLE 94. Global Broad-spectrum antiparasitics Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Global Broad-spectrum antiparasitics Market Size, by Group, 2017-2032 (USD Million)
TABLE 96. Global Broad-spectrum antiparasitics Market Size, by Country, 2017-2032 (USD Million)
TABLE 97. Global Narrow-spectrum antiparasitics Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Global Narrow-spectrum antiparasitics Market Size, by Group, 2017-2032 (USD Million)
TABLE 99. Global Narrow-spectrum antiparasitics Market Size, by Country, 2017-2032 (USD Million)
TABLE 100. Global Antiparasitic Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 101. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 103. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 104. Global Injectable Market Size, by Region, 2017-2032 (USD Million)
TABLE 105. Global Injectable Market Size, by Group, 2017-2032 (USD Million)
TABLE 106. Global Injectable Market Size, by Country, 2017-2032 (USD Million)
TABLE 107. Global Antiparasitic Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 108. Asia-Pacific Antiparasitic Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 109. Asia-Pacific Antiparasitic Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 110. Asia-Pacific Antiparasitic Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 111. Asia-Pacific Antiparasitic Drugs Market Size, by Macrocyclic Lactones, 2017-2032 (USD Million)
TABLE 112. Asia-Pacific Antiparasitic Drugs Market Size, by Veterinary, 2017-2032 (USD Million)
TABLE 113. Asia-Pacific Antiparasitic Drugs Market Size, by Aquaculture, 2017-2032 (USD Million)
TABLE 114. Asia-Pacific Antiparasitic Drugs Market Size, by Companion Animals, 2017-2032 (USD Million)
TABLE 115. Asia-Pacific Antiparasitic Drugs Market Size, by Livestock, 2017-2032 (USD Million)
TABLE 116. Asia-Pacific Antiparasitic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 117. Asia-Pacific Antiparasitic Drugs Market Size, by Spectrum of Activity, 2017-2032 (USD Million)
TABLE 118. Asia-Pacific Antiparasitic Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 119. North America Antiparasitic Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 120. North America Antiparasitic Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 121. North America Antiparasitic Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 122. North America Antiparasitic Drugs Market Size, by Macrocyclic Lactones, 2017-2032 (USD Million)
TABLE 123. North America Antiparasitic Drugs Market Size, by Veterinary, 2017-2032 (USD Million)
TABLE 124. North America Antiparasitic Drugs Market Size, by Aquaculture, 2017-2032 (USD Million)
TABLE 125. North America Antiparasitic Drugs Market Size, by Companion Animals, 2017-2032 (USD Million)
TABLE 126. North America Antiparasitic Drugs Market Size, by Livestock, 2017-2032 (USD Million)
TABLE 127. North America Antiparasitic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 128. North America Antiparasitic Drugs Market Size, by Spectrum of Activity, 2017-2032 (USD Million)
TABLE 129. North America Antiparasitic Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 130. Latin America Antiparasitic Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 131. Latin America Antiparasitic Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 132. Latin America Antiparasitic Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 133. Latin America Antiparasitic Drugs Market Size, by Macrocyclic Lactones, 2017-2032 (USD Million)
TABLE 134. Latin America Antiparasitic Drugs Market Size, by Veterinary, 2017-2032 (USD Million)
TABLE 135. Latin America Antiparasitic Drugs Market Size, by Aquaculture, 2017-2032 (USD Million)
TABLE 136. Latin America Antiparasitic Drugs Market Size, by Companion Animals, 2017-2032 (USD Million)
TABLE 137. Latin America Antiparasitic Drugs Market Size, by Livestock, 2017-2032 (USD Million)
TABLE 138. Latin America Antiparasitic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 139. Latin America Antiparasitic Drugs Market Size, by Spectrum of Activity, 2017-2032 (USD Million)
TABLE 140. Latin America Antiparasitic Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 141. Europe Antiparasitic Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 142. Europe Antiparasitic Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 143. Europe Antiparasitic Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 144. Europe Antiparasitic Drugs Market Size, by Macrocyclic Lactones, 2017-2032 (USD Million)
TABLE 145. Europe Antiparasitic Drugs Market Size, by Veterinary, 2017-2032 (USD Million)
TABLE 146. Europe Antiparasitic Drugs Market Size, by Aquaculture, 2017-2032 (USD Million)
TABLE 147. Europe Antiparasitic Drugs Market Size, by Companion Animals, 2017-2032 (USD Million)
TABLE 148. Europe Antiparasitic Drugs Market Size, by Livestock, 2017-2032 (USD Million)
TABLE 149. Europe Antiparasitic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 150. Europe Antiparasitic Drugs Market Size, by Spectrum of Activity, 2017-2032 (USD Million)
TABLE 151. Europe Antiparasitic Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 152. Middle East Antiparasitic Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 153. Middle East Antiparasitic Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 154. Middle East Antiparasitic Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 155. Middle East Antiparasitic Drugs Market Size, by Macrocyclic Lactones, 2017-2032 (USD Million)
TABLE 156. Middle East Antiparasitic Drugs Market Size, by Veterinary, 2017-2032 (USD Million)
TABLE 157. Middle East Antiparasitic Drugs Market Size, by Aquaculture, 2017-2032 (USD Million)
TABLE 158. Middle East Antiparasitic Drugs Market Size, by Companion Animals, 2017-2032 (USD Million)
TABLE 159. Middle East Antiparasitic Drugs Market Size, by Livestock, 2017-2032 (USD Million)
TABLE 160. Middle East Antiparasitic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 161. Middle East Antiparasitic Drugs Market Size, by Spectrum of Activity, 2017-2032 (USD Million)
TABLE 162. Middle East Antiparasitic Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 163. Africa Antiparasitic Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 164. Africa Antiparasitic Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 165. Africa Antiparasitic Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 166. Africa Antiparasitic Drugs Market Size, by Macrocyclic Lactones, 2017-2032 (USD Million)
TABLE 167. Africa Antiparasitic Drugs Market Size, by Veterinary, 2017-2032 (USD Million)
TABLE 168. Africa Antiparasitic Drugs Market Size, by Aquaculture, 2017-2032 (USD Million)
TABLE 169. Africa Antiparasitic Drugs Market Size, by Companion Animals, 2017-2032 (USD Million)
TABLE 170. Africa Antiparasitic Drugs Market Size, by Livestock, 2017-2032 (USD Million)
TABLE 171. Africa Antiparasitic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 172. Africa Antiparasitic Drugs Market Size, by Spectrum of Activity, 2017-2032 (USD Million)
TABLE 173. Africa Antiparasitic Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 174. Global Antiparasitic Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 175. ASEAN Antiparasitic Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 176. ASEAN Antiparasitic Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 177. ASEAN Antiparasitic Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 178. ASEAN Antiparasitic Drugs Market Size, by Macrocyclic Lactones, 2017-2032 (USD Million)
TABLE 179. ASEAN Antiparasitic Drugs Market Size, by Veterinary, 2017-2032 (USD Million)
TABLE 180. ASEAN Antiparasitic Drugs Market Size, by Aquaculture, 2017-2032 (USD Million)
TABLE 181. ASEAN Antiparasitic Drugs Market Size, by Companion Animals, 2017-2032 (USD Million)
TABLE 182. ASEAN Antiparasitic Drugs Market Size, by Livestock, 2017-2032 (USD Million)
TABLE 183. ASEAN Antiparasitic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 184. ASEAN Antiparasitic Drugs Market Size, by Spectrum of Activity, 2017-2032 (USD Million)
TABLE 185. ASEAN Antiparasitic Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 186. GCC Antiparasitic Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 187. GCC Antiparasitic Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 188. GCC Antiparasitic Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 189. GCC Antiparasitic Drugs Market Size, by Macrocyclic Lactones, 2017-2032 (USD Million)
TABLE 190. GCC Antiparasitic Drugs Market Size, by Veterinary, 2017-2032 (USD Million)
TABLE 191. GCC Antiparasitic Drugs Market Size, by Aquaculture, 2017-2032 (USD Million)
TABLE 192. GCC Antiparasitic Drugs Market Size, by Companion Animals, 2017-2032 (USD Million)
TABLE 193. GCC Antiparasitic Drugs Market Size, by Livestock, 2017-2032 (USD Million)
TABLE 194. GCC Antiparasitic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 195. GCC Antiparasitic Drugs Market Size, by Spectrum of Activity, 2017-2032 (USD Million)
TABLE 196. GCC Antiparasitic Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 197. European Union Antiparasitic Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 198. European Union Antiparasitic Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 199. European Union Antiparasitic Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 200. European Union Antiparasitic Drugs Market Size, by Macrocyclic Lactones, 2017-2032 (USD Million)
TABLE 201. European Union Antiparasitic Drugs Market Size, by Veterinary, 2017-2032 (USD Million)
TABLE 202. European Union Antiparasitic Drugs Market Size, by Aquaculture, 2017-2032 (USD Million)
TABLE 203. European Union Antiparasitic Drugs Market Size, by Companion Animals, 2017-2032 (USD Million)
TABLE 204. European Union Antiparasitic Drugs Market Size, by Livestock, 2017-2032 (USD Million)
TABLE 205. European Union Antiparasitic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 206. European Union Antiparasitic Drugs Market Size, by Spectrum of Activity, 2017-2032 (USD Million)
TABLE 207. European Union Antiparasitic Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 208. BRICS Antiparasitic Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 209. BRICS Antiparasitic Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 210. BRICS Antiparasitic Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 211. BRICS Antiparasitic Drugs Market Size, by Macrocyclic Lactones, 2017-2032 (USD Million)
TABLE 212. BRICS Antiparasitic Drugs Market Size, by Veterinary, 2017-2032 (USD Million)
TABLE 213. BRICS Antiparasitic Drugs Market Size, by Aquaculture, 2017-2032 (USD Million)
TABLE 214. BRICS Antiparasitic Drugs Market Size, by Companion Animals, 2017-2032 (USD Million)
TABLE 215. BRICS Antiparasitic Drugs Market Size, by Livestock, 2017-2032 (USD Million)
TABLE 216. BRICS Antiparasitic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 217. BRICS Antiparasitic Drugs Market Size, by Spectrum of Activity, 2017-2032 (USD Million)
TABLE 218. BRICS Antiparasitic Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 219. G7 Antiparasitic Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 220. G7 Antiparasitic Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 221. G7 Antiparasitic Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 222. G7 Antiparasitic Drugs Market Size, by Macrocyclic Lactones, 2017-2032 (USD Million)
TABLE 223. G7 Antiparasitic Drugs Market Size, by Veterinary, 2017-2032 (USD Million)
TABLE 224. G7 Antiparasitic Drugs Market Size, by Aquaculture, 2017-2032 (USD Million)
TABLE 225. G7 Antiparasitic Drugs Market Size, by Companion Animals, 2017-2032 (USD Million)
TABLE 226. G7 Antiparasitic Drugs Market Size, by Livestock, 2017-2032 (USD Million)
TABLE 227. G7 Antiparasitic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 228. G7 Antiparasitic Drugs Market Size, by Spectrum of Activity, 2017-2032 (USD Million)
TABLE 229. G7 Antiparasitic Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 230. NATO Antiparasitic Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 231. NATO Antiparasitic Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 232. NATO Antiparasitic Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 233. NATO Antiparasitic Drugs Market Size, by Macrocyclic Lactones, 2017-2032 (USD Million)
TABLE 234. NATO Antiparasitic Drugs Market Size, by Veterinary, 2017-2032 (USD Million)
TABLE 235. NATO Antiparasitic Drugs Market Size, by Aquaculture, 2017-2032 (USD Million)
TABLE 236. NATO Antiparasitic Drugs Market Size, by Companion Animals, 2017-2032 (USD Million)
TABLE 237. NATO Antiparasitic Drugs Market Size, by Livestock, 2017-2032 (USD Million)
TABLE 238. NATO Antiparasitic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 239. NATO Antiparasitic Drugs Market Size, by Spectrum of Activity, 2017-2032 (USD Million)
TABLE 240. NATO Antiparasitic Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 241. Global Antiparasitic Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 242. United States Antiparasitic Drugs Market Size, 2017-2032 (USD Million)
TABLE 243. United States Antiparasitic Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 244. United States Antiparasitic Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 245. United States Antiparasitic Drugs Market Size, by Macrocyclic Lactones, 2017-2032 (USD Million)
TABLE 246. United States Antiparasitic Drugs Market Size, by Veterinary, 2017-2032 (USD Million)
TABLE 247. United States Antiparasitic Drugs Market Size, by Aquaculture, 2017-2032 (USD Million)
TABLE 248. United States Antiparasitic Drugs Market Size, by Companion Animals, 2017-2032 (USD Million)
TABLE 249. United States Antiparasitic Drugs Market Size, by Livestock, 2017-2032 (USD Million)
TABLE 250. United States Antiparasitic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 251. United States Antiparasitic Drugs Market Size, by Spectrum of Activity, 2017-2032 (USD Million)
TABLE 252. United States Antiparasitic Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 253. Canada Antiparasitic Drugs Market Size, 2017-2032 (USD Million)
TABLE 254. Canada Antiparasitic Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 255. Canada Antiparasitic Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 256. Canada Antiparasitic Drugs Market Size, by Macrocyclic Lactones, 2017-2032 (USD Million)
TABLE 257. Canada Antiparasitic Drugs Market Size, by Veterinary, 2017-2032 (USD Million)
TABLE 258. Canada Antiparasitic Drugs Market Size, by Aquaculture, 2017-2032 (USD Million)
TABLE 259. Canada Antiparasitic Drugs Market Size, by Companion Animals, 2017-2032 (USD Million)
TABLE 260. Canada Antiparasitic Drugs Market Size, by Livestock, 2017-2032 (USD Million)
TABLE 261. Canada Antiparasitic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 262. Canada Antiparasitic Drugs Market Size, by Spectrum of Activity, 2017-2032 (USD Million)
TABLE 263. Canada Antiparasitic Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 264. Mexico Antiparasitic Drugs Market Size, 2017-2032 (USD Million)
TABLE 265. Mexico Antiparasitic Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 266. Mexico Antiparasitic Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 267. Mexico Antiparasitic Drugs Market Size, by Macrocyclic Lactones, 2017-2032 (USD Million)
TABLE 268. Mexico Antiparasitic Drugs Market Size, by Veterinary, 2017-2032 (USD Million)
TABLE 269. Mexico Antiparasitic Drugs Market Size, by Aquaculture, 2017-2032 (USD Million)
TABLE 270. Mexico Antiparasitic Drugs Market Size, by Companion Animals, 2017-2032 (USD Million)
TABLE 271. Mexico Antiparasitic Drugs Market Size, by Livestock, 2017-2032 (USD Million)
TABLE 272. Mexico Antiparasitic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 273. Mexico Antiparasitic Drugs Market Size, by Spectrum of Activity, 2017-2032 (USD Million)
TABLE 274. Mexico Antiparasitic Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 275. Brazil Antiparasitic Drugs Market Size, 2017-2032 (USD Million)
TABLE 276. Brazil Antiparasitic Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 277. Brazil Antiparasitic Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 278. Brazil Antiparasitic Drugs Market Size, by Macrocyclic Lactones, 2017-2032 (USD Million)
TABLE 279. Brazil Antiparasitic Drugs Market Size, by Veterinary, 2017-2032 (USD Million)
TABLE 280. Brazil Antiparasitic Drugs Market Size, by Aquaculture, 2017-2032 (USD Million)
TABLE 281. Brazil Antiparasitic Drugs Market Size, by Companion Animals, 2017-2032 (USD Million)
TABLE 282. Brazil Antiparasitic Drugs Market Size, by Livestock, 2017-2032 (USD Million)
TABLE 283. Brazil Antiparasitic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 284. Brazil Antiparasitic Drugs Market Size, by Spectrum of Activity, 2017-2032 (USD Million)
TABLE 285. Brazil Antiparasitic Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 286. United Kingdom Antiparasitic Drugs Market Size, 2017-2032 (USD Million)
TABLE 287. United Kingdom Antiparasitic Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 288. United Kingdom Antiparasitic Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 289. United Kingdom Antiparasitic Drugs Market Size, by Macrocyclic Lactones, 2017-2032 (USD Million)
TABLE 290. United Kingdom Antiparasitic Drugs Market Size, by Veterinary, 2017-2032 (USD Million)
TABLE 291. United Kingdom Antiparasitic Drugs Market Size, by Aquaculture, 2017-2032 (USD Million)
TABLE 292. United Kingdom Antiparasitic Drugs Market Size, by Companion Animals, 2017-2032 (USD Million)
TABLE 293. United Kingdom Antiparasitic Drugs Market Size, by Livestock, 2017-2032 (USD Million)
TABLE 294. United Kingdom Antiparasitic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 295. United Kingdom Antiparasitic Drugs Market Size, by Spectrum of Activity, 2017-2032 (USD Million)
TABLE 296. United Kingdom Antiparasitic Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 297. Germany Antiparasitic Drugs Market Size, 2017-2032 (USD Million)
TABLE 298. Germany Antiparasitic Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 299. Germany Antiparasitic Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 300. Germany Antiparasitic Drugs Market Size, by Macrocyclic Lactones, 2017-2032 (USD Million)
TABLE 301. Germany Antiparasitic Drugs Market Size, by Veterinary, 2017-2032 (USD Million)
TABLE 302. Germany Antiparasitic Drugs Market Size, by Aquaculture, 2017-2032 (USD Million)
TABLE 303. Germany Antiparasitic Drugs Market Size, by Companion Animals, 2017-2032 (USD Million)
TABLE 304. Germany Antiparasitic Drugs Market Size, by Livestock, 2017-2032 (USD Million)
TABLE 305. Germany Antiparasitic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 306. Germany Antiparasitic Drugs Market Size, by Spectrum of Activity, 2017-2032 (USD Million)
TABLE 307. Germany Antiparasitic Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 308. France Antiparasitic Drugs Market Size, 2017-2032 (USD Million)
TABLE 309. France Antiparasitic Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 310. France Antiparasitic Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 311. France Antiparasitic Drugs Market Size, by Macrocyclic Lactones, 2017-2032 (USD Million)
TABLE 312. France Antiparasitic Drugs Market Size, by Veterinary, 2017-2032 (USD Million)
TABLE 313. France Antiparasitic Drugs Market Size, by Aquaculture, 2017-2032 (USD Million)
TABLE 314. France Antiparasitic Drugs Market Size, by Companion Animals, 2017-2032 (USD Million)
TABLE 315. France Antiparasitic Drugs Market Size, by Livestock, 2017-2032 (USD Million)
TABLE 316. France Antiparasitic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 317. France Antiparasitic Drugs Market Size, by Spectrum of Activity, 2017-2032 (USD Million)
TABLE 318. France Antiparasitic Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 319. Russia Antiparasitic Drugs Market Size, 2017-2032 (USD Million)
TABLE 320. Russia Antiparasitic Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 321. Russia Antiparasitic Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 322. Russia Antiparasitic Drugs Market Size, by Macrocyclic Lactones, 2017-2032 (USD Million)
TABLE 323. Russia Antiparasitic Drugs Market Size, by Veterinary, 2017-2032 (USD Million)
TABLE 324. Russia Antiparasitic Drugs Market Size, by Aquaculture, 2017-2032 (USD Million)
TABLE 325. Russia Antiparasitic Drugs Market Size, by Companion Animals, 2017-2032 (USD Million)
TABLE 326. Russia Antiparasitic Drugs Market Size, by Livestock, 2017-2032 (USD Million)
TABLE 327. Russia Antiparasitic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 328. Russia Antiparasitic Drugs Market Size, by Spectrum of Activity, 2017-2032 (USD Million)
TABLE 329. Russia Antiparasitic Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 330. Italy Antiparasitic Drugs Market Size, 2017-2032 (USD Million)
TABLE 331. Italy Antiparasitic Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 332. Italy Antiparasitic Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 333. Italy Antiparasitic Drugs Market Size, by Macrocyclic Lactones, 2017-2032 (USD Million)
TABLE 334. Italy Antiparasitic Drugs Market Size, by Veterinary, 2017-2032 (USD Million)
TABLE 335. Italy Antiparasitic Drugs Market Size, by Aquaculture, 2017-2032 (USD Million)
TABLE 336. Italy Antiparasitic Drugs Market Size, by Companion Animals, 2017-2032 (USD Million)
TABLE 337. Italy Antiparasitic Drugs Market Size, by Livestock, 2017-2032 (USD Million)
TABLE 338. Italy Antiparasitic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 339. Italy Antiparasitic Drugs Market Size, by Spectrum of Activity, 2017-2032 (USD Million)
TABLE 340. Italy Antiparasitic Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 341. Spain Antiparasitic Drugs Market Size, 2017-2032 (USD Million)
TABLE 342. Spain Antiparasitic Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 343. Spain Antiparasitic Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 344. Spain Antiparasitic Drugs Market Size, by Macrocyclic Lactones, 2017-2032 (USD Million)
TABLE 345. Spain Antiparasitic Drugs Market Size, by Veterinary, 2017-2032 (USD Million)
TABLE 346. Spain Antiparasitic Drugs Market Size, by Aquaculture, 2017-2032 (USD Million)
TABLE 347. Spain Antiparasitic Drugs Market Size, by Companion Animals, 2017-2032 (USD Million)
TABLE 348. Spain Antiparasitic Drugs Market Size, by Livestock, 2017-2032 (USD Million)
TABLE 349. Spain Antiparasitic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 350. Spain Antiparasitic Drugs Market Size, by Spectrum of Activity, 2017-2032 (USD Million)
TABLE 351. Spain Antiparasitic Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 352. China Antiparasitic Drugs Market Size, 2017-2032 (USD Million)
TABLE 353. China Antiparasitic Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 354. China Antiparasitic Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 355. China Antiparasitic Drugs Market Size, by Macrocyclic Lactones, 2017-2032 (USD Million)
TABLE 356. China Antiparasitic Drugs Market Size, by Veterinary, 2017-2032 (USD Million)
TABLE 357. China Antiparasitic Drugs Market Size, by Aquaculture, 2017-2032 (USD Million)
TABLE 358. China Antiparasitic Drugs Market Size, by Companion Animals, 2017-2032 (USD Million)
TABLE 359. China Antiparasitic Drugs Market Size, by Livestock, 2017-2032 (USD Million)
TABLE 360. China Antiparasitic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 361. China Antiparasitic Drugs Market Size, by Spectrum of Activity, 2017-2032 (USD Million)
TABLE 362. China Antiparasitic Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 363. India Antiparasitic Drugs Market Size, 2017-2032 (USD Million)
TABLE 364. India Antiparasitic Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 365. India Antiparasitic Drugs Market Size, by Benzimidazoles, 2017-2032 (USD Million)
TABLE 366. India Antiparasitic Dr

Companies Mentioned

  • Adva Care Pharma
  • Algen Healthcare Ltd.
  • Amneal Pharmaceuticals LLC
  • Bayer AG
  • Ben Pharmaceuticals
  • Centurion Laboratories Private Limited
  • Cipla Ltd.
  • Consern Pharma Limited
  • Dr.Reddys Laboratories Inc.
  • F. Hoffmann-La Roche AG
  • Fredun Group
  • Garcia Life Sciences
  • Glaxosmithkline PLC
  • Healthy Life Pharma Private Limited
  • Ipca Laboratories
  • Jackson Laboratories Pvt Ltd.
  • Mankind Pharma
  • Merck KgaA
  • Novartis AG
  • Sanofi
  • Soigner Pharma by Arlak Biotech
  • Sriwalls Health Care
  • Taj Life Sciences Pvt. Ltd.
  • Weefsel Pharma
  • Zydus Group

Table Information

Report AttributeDetails
No. of Pages187
PublishedSeptember 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 23.3 Billion
Forecasted Market Value ( USD ) by 2032 $ 30.98 Billion
Compound Annual Growth Rate4.8%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Global Antiparasitic Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Global Antiparasitic Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 120 Pages
  • Global
From
Antiparasitic Drugs Market Report 2026 - Product Image

Antiparasitic Drugs Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Antiparasitic Drugs Market Outlook 2026-2034: Market Share and Growth Analysis by Drug Type, Route of Administration, Distribution Channel, End-User - Product Image

Antiparasitic Drugs Market Outlook 2026-2034: Market Share and Growth Analysis by Drug Type, Route of Administration, Distribution Channel, End-User

  • Report
  • 160 Pages
  • Global
From
Antiparasitic Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035 - Product Image

Antiparasitic Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035

  • Report
  • 135 Pages
  • Global
From
Anthelmintic Drugs Market - Global Forecast 2026-2032 - Product Image

Anthelmintic Drugs Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From

About the Antiparasitic Agent Market

The Antiparasitic Agent market is a subset of the Infectious Diseases Drugs market, which focuses on the development and sale of drugs used to treat parasitic infections. Antiparasitic Agents are used to treat a variety of parasitic infections, including malaria, schistosomiasis, and leishmaniasis. These drugs are typically administered orally, intravenously, or topically, depending on the type of infection. Antiparasitic Agents are often used in combination with other drugs to ensure the most effective treatment. The Antiparasitic Agent market is highly competitive, with many companies offering a variety of drugs. Some of the major players in the market include GlaxoSmithKline, Merck & Co., Sanofi, Pfizer, and Novartis. Other companies, such as Johnson & Johnson, Bayer, and AstraZeneca, also offer Antiparasitic Agents. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.